NCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
Clinical Trials
10 trialsNCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT04869371 2022-12-29
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT04356430 2022-12-16
Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05167175 2022-10-25
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT05188911 2022-01-12
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
Fudan University
Unknown
NCT05156450 2021-12-14
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
West China Hospital
Phase 2 Unknown
NCT03356912 2017-12-14
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
Consorzio Oncotech
Phase 2 Unknown
NCT02208583 2014-08-05
Molecular Phenotype Changes and Personalized Treatment for CRPC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT00003633 2013-12-19
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Unknown